New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants

Drug Resistance Updates

Volumn 20, Issue , 2015, Pages 1-11

  Gatti, Laura ^a   Cassinelli, Giuliana ^a   Zaffaroni, Nadia ^a   Lanzi, Cinzia ^a   Perego, Paola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cell death; Drug resistance; Lysosomes; Mitochondria; Platinum compounds

Indexed keywords

CISPLATIN; DNA; MITOCHONDRIAL DNA; PLATINUM DERIVATIVE; PLATINUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COMPARTMENTALIZATION; CELL DEATH; CELL MEMBRANE; CYTOSKELETON; CYTOTOXICITY; DRUG ACTIVITY; DRUG RESISTANCE; ENDOPLASMIC RETICULUM STRESS; ENDOSOME; HUMAN; IMMUNOMODULATION; LYSOSOME; MITOCHONDRION; PHENOTYPE; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; DNA DAMAGE; DRUG EFFECTS;

CELL MEMBRANE; CYTOSKELETON; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOMODULATION; LYSOSOMES; MITOCHONDRIA; ORGANOPLATINUM COMPOUNDS;

EID: 84930759388     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2015.04.001     Document Type: Review

References (152)

1. O.D. Abaan, and J.A. Toretsky PTPL1: a large phosphatase with a split personality Cancer Metastasis Rev. 27 2 2008 205 214
2. S. Abu-Hamad, S. Sivan, and V. Shoshan-Barmatz The expression level of the voltage-dependent anion channel controls life and death of the cell Proc. Natl. Acad. Sci. U. S. A. 103 15 2006 5787 5792
3. S. Aits, and M. Jaattela Lysosomal cell death at a glance J. Cell Sci. 126 Pt 9 2013 1905 1912
4. P.A. Andrews, and S.B. Howell Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance Cancer Cells 2 2 1990 35 43
5. P.A. Andrews, J.A. Jones, N.M. Varki, and S.B. Howell Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma Cancer Commun. 2 2 1990 93 100
6. L. Apetoh, F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, and A. Criollo Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat. Med. 13 9 2007 1050 1059
7. H. Appelqvist, C. Nilsson, B. Garner, A.J. Brown, K. Kagedal, and K. Ollinger Attenuation of the lysosomal death pathway by lysosomal cholesterol accumulation Am. J. Pathol. 178 2 2011 629 639
8. D. Arnoult, P. Parone, J.C. Martinou, B. Antonsson, J. Estaquier, and J.C. Ameisen Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli J. Cell Biol. 159 6 2002 923 929
9. Y.G. Assaraf The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis Drug Resist. Updates 9 4-5 2006 227 246
10. C. Batandier, X. Leverve, and E. Fontaine Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I J. Biol. Chem. 279 17 2004 17197 17204
11. G.L. Beretta, V. Benedetti, G. Cossa, Y.G. Assaraf, E. Bram, and L. Gatti Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin Biochem. Pharmacol. 79 8 2010 1108 1117
12. G.L. Beretta, S.C. Righetti, L. Lombardi, F. Zunino, and P. Perego Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells Ultrastruct. Pathol. 26 5 2002 331 334
13. V.A. Boussiotis, P. Chatterjee, and L. Li Biochemical signaling of PD-1 on T cells and its functional implications Cancer J. 20 4 2014 265 271
14. F. Brandizzi, and C. Barlowe Organization of the ER-golgi interface for membrane traffic control Nat. Rev.: Mol. Cell Biol. 14 6 2013 382 392
15. D.G. Breckenridge, M. Germain, J.P. Mathai, M. Nguyen, and G.C. Shore Regulation of apoptosis by endoplasmic reticulum pathways Oncogene 22 53 2003 8608 8618
16. K. Burger, B. Muhl, T. Harasim, M. Rohrmoser, A. Malamoussi, and M. Orban Chemotherapeutic drugs inhibit ribosome biogenesis at various levels J. Biol. Chem. 285 16 2010 12416 12425
17. A. Castagna, P. Antonioli, H. Astner, M. Hamdan, S.C. Righetti, and P. Perego A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431 Proteomics 4 10 2004 3246 3267
18. V. Cepeda, M.A. Fuertes, J. Castilla, C. Alonso, C. Quevedo, and J.M. Perez Biochemical mechanisms of cisplatin cytotoxicity Anti-cancer Agents Med. Chem. 7 1 2007 3 18
19. S.S. Chauhan, X.J. Liang, A.W. Su, A. Pai-Panandiker, D.W. Shen, and J.A. Hanover Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines Br. J. Cancer 88 8 2003 1327 1334
20. M. Colombini VDAC: the channel at the interface between mitochondria and the cytosol Mol. Cell. Biochem. 256-257 1-2 2004 107 115
21. G. Cossa, L. Gatti, F. Zunino, and P. Perego Strategies to improve the efficacy of platinum compounds Curr. Med. Chem. 16 19 2009 2355 2365
22. P. Costantini, A.S. Belzacq, H.L. Vieira, N. Larochette, M.A. de Pablo, and N. Zamzami Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces bcl-2-independent permeability transition pore opening and apoptosis Oncogene 19 2 2000 307 314
23. F. Courjault-Gautier, C. Le Grimellec, M.C. Giocondi, and H.J. Toutain Modulation of sodium-coupled uptake and membrane fluidity by cisplatin in renal proximal tubular cells in primary culture and brush-border membrane vesicles Kidney Int. 47 4 1995 1048 1056
24. K.J. Cullen, Z. Yang, L. Schumaker, and Z. Guo Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer J. Bioenerg. Biomembr. 39 1 2007 43 50
25. J.B. Custodio, C.M. Cardoso, M.S. Santos, L.M. Almeida, J.A. Vicente, and M.A. Fernandes Cisplatin impairs rat liver mitochondrial functions by inducing changes on membrane ion permeability: prevention by thiol group protecting agents Toxicology 259 1-2 2009 18 24
26. J.C. Dabrowiak, J. Goodisman, and A.K. Souid Kinetic study of the reaction of cisplatin with thiols Drug Metab. Dispos.: Biol. Fate Chem. 30 12 2002 1378 1384
27. M.T. Dimanche-Boitrel, O. Meurette, A. Rebillard, and S. Lacour Role of early plasma membrane events in chemotherapy-induced cell death Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy 8 1-2 2005 5 14
28. E.W. Duiker, E.G. de Vries, D. Mahalingam, G.J. Meersma, W. Boersma-van Ek, and H. Hollema Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model Clin. Cancer Res. 15 6 2009 2048 2057
29. L. Emert-Sedlak, S. Shangary, A. Rabinovitz, M.B. Miranda, S.M. Delach, and D.E. Johnson Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death Mol. Cancer Ther. 4 5 2005 733 742
30. S. Fais, A. De Milito, and F. Lozupone The role of FAS to ezrin association in FAS-mediated apoptosis Apoptosis: Int. J. Progr. Cell Death 10 5 2005 941 947
31. N. Fehrenbacher, L. Bastholm, T. Kirkegaard-Sorensen, B. Rafn, T. Bottzauw, and C. Nielsen Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2 Cancer Res. 68 16 2008 6623 6633
32. J.I. Fletcher, M. Haber, M.J. Henderson, and M.D. Norris ABC transporters in cancer: more than just drug efflux pumps Nat. Rev. Cancer 10 2 2010 147 156
33. S. Frese, A. Schuller, M. Frese-Schaper, M. Gugger, and R.A. Schmid Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer Anticancer Res. 29 8 2009 2905 2911
34. L. Galluzzi, J.M. Bravo-San Pedro, and G. Kroemer Organelle-specific initiation of cell death Nat. Cell Biol. 16 8 2014 728 736
35. L. Galluzzi, I. Vitale, J. Michels, C. Brenner, G. Szabadkai, and A. Harel-Bellan Systems biology of cisplatin resistance: past, present and future Cell Death Disease 5 2014 e1257
36. L. Galluzzi, I. Vitale, L. Senovilla, T. Eisenberg, D. Carmona-Gutierrez, and E. Vacchelli Independent transcriptional reprogramming and apoptosis induction by cisplatin Cell Cycle 11 18 2012 3472 3480
37. L. Gatti, V. Benedetti, M. De Cesare, E. Corna, R. Cincinelli, and N. Zaffaroni Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells J. Inorg. Biochem. 113 2012 94 101
38. L. Gatti, G. Cossa, S. Tinelli, N. Carenini, N. Arrighetti, and M. Pennati Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment J. Pharmacol. Exp. Ther. 348 3 2014 360 371
39. F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, and C. Ortiz Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors Nat. Med. 15 10 2009 1170 1178
40. R.M. Glasspool, J.M. Teodoridis, and R. Brown Epigenetics as a mechanism driving polygenic clinical drug resistance Br. J. Cancer 94 8 2006 1087 1092
41. E.B. Golden, D. Frances, I. Pellicciotta, S. Demaria, M. Helen Barcellos-Hoff, and S.C. Formenti Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death Oncoimmunology 3 2014 e28518
42. O.W. Griffith, and A. Meister Origin and turnover of mitochondrial glutathione Proc. Natl. Acad. Sci. U. S. A. 82 14 1985 4668 4672
43. L. Groth-Pedersen, S. Aits, E. Corcelle-Termeau, N.H. Petersen, J. Nylandsted, and M. Jaattela Identification of cytoskeleton-associated proteins essential for lysosomal stability and survival of human cancer cells PLoS ONE 7 10 2012 e45381
44. M. Gyrd-Hansen, T. Farkas, N. Fehrenbacher, L. Bastholm, M. Hoyer-Hansen, and F. Elling Apoptosome-independent activation of the lysosomal cell death pathway by caspase-9 Mol. Cell. Biol. 26 21 2006 7880 7891
45. B. Hamel, S. Malachowski, L. Vancamp, and E.J. McGroarty The effect of CaCl2 and verapamil on the binding of cisplatin to cultures of normal and transformed human fibroblasts Cancer Biochem. Biophys. 11 2 1990 155 168
46. S.V. Hato, I.J. de Vries, and W.J. Lesterhuis STATing the importance of immune modulation by platinum chemotherapeutics Oncoimmunology 1 2 2012 234 236
47. S.V. Hato, A. Khong, I.J. de Vries, and W.J. Lesterhuis Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics Clin. Cancer Res. 20 11 2014 2831 2837
48. R.S. Herbst, S.G. Eckhardt, R. Kurzrock, S. Ebbinghaus, P.J. O'Dwyer, and M.S. Gordon Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J. Clin. Oncol. 28 17 2010 2839 2846
49. N. Hirokawa, R. Nitta, and Y. Okada The mechanisms of kinesin motor motility: lessons from the monomeric motor KIF1A Nat. Rev. Mol. Cell Biol. 10 12 2009 877 884
50. S.B. Howell, R. Safaei, C.A. Larson, and M.J. Sailor Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs Mol. Pharmacol. 77 6 2010 887 894
51. C.R. Huang, Z.X. Jin, L. Dong, X.P. Tong, S. Yue, and T. Kawanami Cisplatin augments FAS-mediated apoptosis through lipid rafts Anticancer Res. 30 6 2010 2065 2071
52. Z. Huang, Y. Tong, J. Wang, and Y. Huang NMR studies of the relationship between the changes of membrane lipids and the cisplatin-resistance of A549/DDP cells Cancer Cell Int. 3 1 2003 5
53. M. Inoue, E.F. Sato, M. Nishikawa, A.M. Park, Y. Kira, and I. Imada Mitochondrial generation of reactive oxygen species and its role in aerobic life Curr. Med. Chem. 10 23 2003 2495 2505
54. M. Jensen, M. Bjerring, N.C. Nielsen, and W. Nerdal Cisplatin interaction with phosphatidylserine bilayer studied by solid-state NMR spectroscopy J. Biol. Inorg. Chem. 15 2 2010 213 223
55. C.C. Jiang, Z.G. Mao, K.A. Avery-Kiejda, M. Wade, P. Hersey, and X.D. Zhang Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells Carcinogenesis 30 2 2009 197 204
56. S. Jiang, J. Cai, D.C. Wallace, and D.P. Jones Cytochrome c-mediated apoptosis in cells lacking mitochondrial DNA. Signaling pathway involving release and caspase 3 activation is conserved J. Biol. Chem. 274 42 1999 29905 29911
57. A.C. Johansson, H. Appelqvist, C. Nilsson, K. Kagedal, K. Roberg, and K. Ollinger Regulation of apoptosis-associated lysosomal membrane permeabilization Apoptosis: Int. J. Progr. Cell Death 15 5 2010 527 540
58. M. Kartalou, and J.M. Essigmann Recognition of cisplatin adducts by cellular proteins Mutat. Res. 478 1-2 2001 1 21
59. L. Kelland The resurgence of platinum-based cancer chemotherapy Nat. Rev. Cancer 7 8 2007 573 584
60. K. Kondo, S. Yamasaki, N. Inoue, T. Sugie, N. Teratani, and T. Kan Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma Surg. Today 36 11 2006 966 974
61. R. Koschny, H. Holland, J. Sykora, T.L. Haas, M.R. Sprick, and T.M. Ganten Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis Clin. Cancer Res. 13 11 2007 3403 3412
62. R. Koster, M.A. van Vugt, H. Timmer-Bosscha, J.A. Gietema, and S. de Jong Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer Expert Rev. Mol. Med. 15 2013 e12
63. W.C. Kuo, K.T. Yang, S.L. Hsieh, and M.Z. Lai Ezrin is a negative regulator of death receptor-induced apoptosis Oncogene 29 9 2010 1374 1383
64. J.Q. Kwong, M.S. Henning, A.A. Starkov, and G. Manfredi The mitochondrial respiratory chain is a modulator of apoptosis J. Cell Biol. 179 6 2007 1163 1177
65. S. Lacour, A. Hammann, S. Grazide, D. Lagadic-Gossmann, A. Athias, and O. Sergent Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells Cancer Res. 64 10 2004 3593 3598
66. S. Lacour, O. Micheau, A. Hammann, V. Drouineaud, J. Tschopp, and E. Solary Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells Oncogene 22 12 2003 1807 1816
67. R.A. Lake, and R.G. van der Most A better way for a cancer cell to die N. Engl. J. Med. 354 23 2006 2503 2504
68. L. Lalier, P.F. Cartron, P. Juin, S. Nedelkina, S. Manon, and B. Bechinger Bax activation and mitochondrial insertion during apoptosis Apoptosis: Int. J. Programmed Cell Death 12 5 2007 887 896
69. A.C. Lee, X. Xu, E. Blachly-Dyson, M. Forte, and M. Colombini The role of yeast VDAC genes on the permeability of the mitochondrial outer membrane J. Membr. Biol. 161 2 1998 173 181
70. Y. Lei, B.R. Henderson, C. Emmanuel, P.R. Harnett, and A. Defazio Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis Oncogene 34 4 2014 485 495
71. W.J. Lesterhuis, C.J. Punt, S.V. Hato, D. Eleveld-Trancikova, B.J. Jansen, and S. Nierkens Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice J. Clin. Investig. 121 8 2011 3100 3108
72. B.C. Liang, and E. Ullyatt Increased sensitivity to cis-diamminedichloroplatinum induced apoptosis with mitochondrial DNA depletion Cell Death Differ. 5 8 1998 694 701
73. X.J. Liang, S. Mukherjee, D.W. Shen, F.R. Maxfield, and M.M. Gottesman Endocytic recycling compartments altered in cisplatin-resistant cancer cells Cancer Res. 66 4 2006 2346 2353
74. X.J. Liang, D.W. Shen, and M.M. Gottesman A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells J. Inorg. Biochem. 98 10 2004 1599 1606
75. M.J. Ligtenberg, L. Kruijshaar, F. Buijs, M. van Meijer, S.V. Litvinov, and J. Hilkens Cell-associated episialin is a complex containing two proteins derived from a common precursor J. Biol. Chem. 267 9 1992 6171 6177
76. Y. Lin, Z. Wang, L. Liu, and L. Chen Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells Lung Cancer 71 3 2011 291 297
77. S. Linder, and M.C. Shoshan Lysosomes and endoplasmic reticulum: targets for improved, selective anticancer therapy Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 8 4 2005 199 204
78. M. Loeffler, and G. Kroemer The mitochondrion in cell death control: certainties and incognita Exp. Cell Res. 256 1 2000 19 26
79. A. Lopergolo, V. Nicolini, E. Favini, L. Dal Bo, M. Tortoreto, and D. Cominetti Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer J. Clin. Endocrinol. Metab. 99 2 2014 498 509
80. G. Los, K. Benbatoul, D.P. Gately, R. Barton, R. Christen, and K.T. Robbins Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer Clin. Cancer Res. 5 7 1999 1610 1618
81. Y. Ma, and L.M. Hendershot The role of the unfolded protein response in tumour development: friend or foe? Nat. Rev.: Cancer 4 12 2004 966 977
82. A. Mandic, J. Hansson, S. Linder, and M.C. Shoshan Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling J. Biol. Chem. 278 11 2003 9100 9106
83. A. Mandic, K. Viktorsson, L. Strandberg, T. Heiden, J. Hansson, and S. Linder Calpain-mediated bid cleavage and calpain-independent bak modulation: two separate pathways in cisplatin-induced apoptosis Mol. Cell. Biol. 22 9 2002 3003 3013
84. I. Martins, O. Kepp, F. Schlemmer, S. Adjemian, M. Tailler, and S. Shen Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress Oncogene 30 10 2011 1147 1158
85. I. Martins, Y. Wang, M. Michaud, Y. Ma, A.Q. Sukkurwala, and S. Shen Molecular mechanisms of ATP secretion during immunogenic cell death Cell Death Differ. 21 1 2014 79 91
86. I. Masgras, S. Carrera, P.J. de Verdier, P. Brennan, A. Majid, and W. Makhtar Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21 J. Biol. Chem. 287 13 2012 9845 9854
87. O. Micheau, E. Solary, A. Hammann, and M.T. Dimanche-Boitrel Fas ligand-independent, FADD-mediated activation of the fas death pathway by anticancer drugs J. Biol. Chem. 274 12 1999 7987 7992
88. S. Mizutani, Y. Miyato, Y. Shidara, S. Asoh, A. Tokunaga, and T. Tajiri Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs Cancer Sci. 100 9 2009 1680 1687
89. A. Morimoto, S. Serada, T. Enomoto, A. Kim, S. Matsuzaki, and T. Takahashi Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner Oncotarget 5 17 2014 7776 7787
90. F. Muggia Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer Gynecol. Oncol. 112 1 2009 275 281
91. T. Murakami, I. Shibuya, T. Ise, Z.S. Chen, S. Akiyama, and M. Nakagawa Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance Int. J. Cancer Journal International du Cancer 93 6 2001 869 874
92. A.L. Neisch, and R.G. Fehon Ezrin, radixin and moesin: key regulators of membrane-cortex interactions and signaling Curr. Opin. Cell Biol. 23 4 2011 377 382
93. V. Nicolini, G. Cassinelli, G. Cuccuru, I. Bongarzone, G. Petrangolini, and M. Tortoreto Interplay between ret and fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells Biochem. Pharmacol. 82 7 2011 778 788
94. C. Nilsson, K. Roberg, R.C. Grafstrom, and K. Ollinger Intrinsic differences in cisplatin sensitivity of head and neck cancer cell lines: correlation to lysosomal pH Head Neck 32 9 2010 1185 1194
95. M. Obeid, A. Tesniere, F. Ghiringhelli, G.M. Fimia, L. Apetoh, and J.L. Perfettini Calreticulin exposure dictates the immunogenicity of cancer cell death Nat. Med. 13 1 2007 54 61
96. O.A. Olivero, C. Semino, A. Kassim, D.M. Lopez-Larraza, and M.C. Poirier Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells Mutat. Res. 346 4 1995 221 230
97. M.F. Osborn, J.D. White, M.M. Haley, and V.J. DeRose Platinum-RNA modifications following drug treatment in S. cerevisiae identified by click chemistry and enzymatic mapping ACS Chem. Biol. 9 10 2014 2404 2411
98. M.E. Palm, C.F. Weise, C. Lundin, G. Wingsle, Y. Nygren, and E. Bjorn Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro Proc. Natl. Acad. Sci. U. S. A. 108 17 2011 6951 6956
99. T. Panaretakis, O. Kepp, U. Brockmeier, A. Tesniere, A.C. Bjorklund, and D.C. Chapman Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death EMBO J. 28 5 2009 578 590
100. C.B. Park, and N.G. Larsson Mitochondrial DNA mutations in disease and aging J. Cell Biol. 193 5 2011 809 818
101. S.Y. Park, I. Chang, J.Y. Kim, S.W. Kang, S.H. Park, and K. Singh Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase J. Biol. Chem. 279 9 2004 7512 7520
102. I. Paul, A.D. Chacko, I. Stasik, S. Busacca, N. Crawford, and F. McCoy Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer Cell Death Dis. 3 2012 e449
103. B. Pennarun, A. Meijer, E.G. de Vries, J.H. Kleibeuker, F. Kruyt, and S. de Jong Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer Biochim. Biophys. acta 1805 2 2010 123 140
104. M. Pennati, A. Lopergolo, V. Profumo, M. De Cesare, S. Sbarra, and R. Valdagni miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells Biochem. Pharmacol. 87 4 2014 579 597
105. P. Perego, L. Gatti, and G.L. Beretta The ABC of glycosylation Nat. Rev. Cancer 10 7 2010 523-c1
106. P. Perego, S. Romanelli, N. Carenini, I. Magnani, R. Leone, and A. Bonetti Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to taxol Ann. Oncol. 9 4 1998 423 430
107. H. Puthalakath, L.A. O'Reilly, P. Gunn, L. Lee, P.N. Kelly, and N.D. Huntington ER stress triggers apoptosis by activating BH3-only protein bim Cell 129 7 2007 1337 1349
108. C.A. Rabik, M.L. Fishel, J.L. Holleran, K. Kasza, M.R. Kelley, and M.J. Egorin Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress J. Pharmacol. Exp. Ther. 327 2 2008 442 452
109. A. Rebillard, S. Jouan-Lanhouet, E. Jouan, P. Legembre, M. Pizon, and O. Sergent Cisplatin-induced apoptosis involves a fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells Eur. J. Cancer 46 8 2010 1445 1455
110. A. Rebillard, D. Lagadic-Gossmann, and M.T. Dimanche-Boitrel Cisplatin cytotoxicity: DNA and plasma membrane targets Curr. Med. Chem. 15 26 2008 2656 2663
111. A. Rebillard, X. Tekpli, O. Meurette, O. Sergent, G. LeMoigne-Muller, and L. Vernhet Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells Cancer Res. 67 16 2007 7865 7874
112. R.M. Reddy, W.S. Tsai, M.F. Ziauddin, J. Zuo, G.W. Cole Jr., and J.B. Maxhimer Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand J. Thorac. Cardiovasc. Surg. 128 6 2004 883 891
113. J. Ren, N. Agata, D. Chen, Y. Li, W.H. Yu, and L. Huang Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents Cancer Cell 5 2 2004 163 175
114. B. Rosenberg, L. Vancamp, and T. Krigas Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode Nature 205 1965 698 699
115. S.S. Sabharwal, and P.T. Schumacker Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat. Rev. Cancer 14 11 2014 709 721
116. R. Safaei, B.J. Larson, T.C. Cheng, M.A. Gibson, S. Otani, and W. Naerdemann Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells Mol. Cancer Ther. 4 10 2005 1595 1604
117. S.M. Sancho-Martinez, L. Prieto-Garcia, M. Prieto, J.M. Lopez-Novoa, and F.J. Lopez-Hernandez Subcellular targets of cisplatin cytotoxicity: an integrated view Pharmacol. Ther. 136 1 2012 35 55
118. F.M. Santandreu, P. Roca, and J. Oliver Uncoupling protein-2 knockdown mediates the cytotoxic effects of cisplatin Free Radic. Biol. Med. 49 4 2010 658 666
119. N.A. Santos, C.S. Catao, N.M. Martins, C. Curti, M.L. Bianchi, and A.C. Santos Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria Arch. Toxicol. 81 7 2007 495 504
120. S.M. Schleicher, L. Moretti, V. Varki, and B. Lu Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: implications for future therapeutic approaches Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 13 3 2010 79 86
121. D. Schneiderman, J.M. Kim, M. Senterman, and B.K. Tsang Sustained suppression of fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells Apoptosis: Int. J. Progr. Cell Death 4 4 1999 271 281
122. M. Schroder, and R.J. Kaufman The mammalian unfolded protein response Ann. Rev. Biochem. 74 2005 739 789
123. L.L. Scurr, A.D. Guminski, Y.E. Chiew, R.L. Balleine, R. Sharma, and Y. Lei Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer Clin. Cancer Res. 14 21 2008 6924 6932
124. B. Segui, and P. Legembre Redistribution of CD95 into the lipid rafts to treat cancer cells? Recent Pat. Anti-cancer Drug Discov. 5 1 2010 22 28
125. O. Sharaf el dein, C. Gallerne, C. Brenner, and C. Lemaire Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents Biochem. Pharmacol. 83 9 2012 1172 1182
126. S. Sharma, C. Santiskulvong, L.A. Bentolila, J. Rao, O. Dorigo, and J.K. Gimzewski Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells Nanomed.: Nanotechnol. Biol. Med. 8 5 2012 757 766
127. S.V. Sharma, D.Y. Lee, B. Li, M.P. Quinlan, F. Takahashi, and S. Maheswaran A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 1 2010 69 80
128. G. Singh, and E. Maniccia-Bozzo Evidence for lack of mitochondrial DNA repair following cis-dichlorodiammineplatinum treatment Cancer Chemother. Pharmacol. 26 2 1990 97 100
129. J.C. Soria, E. Smit, D. Khayat, B. Besse, X. Yang, and C.P. Hsu Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer J. Clin. Oncol. 28 9 2010 1527 1533
130. M. Suwalsky, P. Hernandez, F. Villena, and C.P. Sotomayor The anticancer drug cisplatin interacts with the human erythrocyte membrane Z. Naturforsch. C: J. Biosci. 55 5-6 2000 461 466
131. N. Tajeddine, L. Galluzzi, O. Kepp, E. Hangen, E. Morselli, and L. Senovilla Hierarchical involvement of bak, VDAC1 and bax in cisplatin-induced cell death Oncogene 27 30 2008 4221 4232
132. S. Tang, W. Huang, M. Zhong, L. Yin, H. Jiang, and S. Hou Identification keratin 1 as a cDDP-resistant protein in nasopharyngeal carcinoma cell lines J. Proteomics 75 8 2012 2352 2360
133. A. Tesniere, T. Panaretakis, O. Kepp, L. Apetoh, F. Ghiringhelli, and L. Zitvogel Molecular characteristics of immunogenic cancer cell death Cell Death Differ. 15 1 2008 3 12
134. I.N. Todor, N.Y. Lukyanova, and V.F. Chekhun The lipid content of cisplatin- and doxorubicin-resistant MCF-7 human breast cancer cells Exp. Oncol. 34 2 2012 97 100
135. B. Turk, and V. Turk Lysosomes as "suicide bags" in cell death: myth or reality? J. Biol. Chem. 284 33 2009 21783 21787
136. J.P. Upton, L. Wang, D. Han, E.S. Wang, N.E. Huskey, and L. Lim IRE1alpha cleaves select microRNAs during ER stress to derepress translation of proapoptotic caspase-2 Science 338 6108 2012 818 822
137. L. Vande Walle, M. Lamkanfi, and P. Vandenabeele The mitochondrial serine protease HtrA2/Omi: an overview Cell Death Differ. 15 3 2008 453 460
138. R. Vasko, G.A. Mueller, A.K. von Jaschke, A.R. Asif, and H. Dihazi Impact of cisplatin administration on protein expression levels in renal cell carcinoma: a proteomic analysis Eur. J. Pharmacol. 670 1 2011 50 57
139. R.P. Wernyj, and P.J. Morin Molecular mechanisms of platinum resistance: still searching for the Achilles' heel Drug Resist. Updates: Rev. Comment. Antimicrob. Anticancer Chemother. 7 4-5 2004 227 232
140. P. Widlak, and W.T. Garrard Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G J. Cell. Biochem. 94 6 2005 1078 1087
141. J. Woodcock Sphingosine and ceramide signalling in apoptosis IUBMB Life 58 8 2006 462 466
142. Z.Y. Xiao, W. Wu, N. Eagleton, H.Q. Chen, J. Shao, and H. Teng Silencing fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin World J. Gastroenterol. 16 1 2010 112 118
143. Y. Xu, D. Li, L. Zeng, C. Wang, L. Zhang, and Y. Wang Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress associated apoptosis in HeLa cells Mol. Med. Rep. 11 1 2014 189 195
144. T. Yamazaki, D. Hannani, V. Poirier-Colame, S. Ladoire, C. Locher, and A. Sistigu Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists Cell Death Differ. 21 1 2014 69 78
145. Z. Yang, L.M. Schumaker, M.J. Egorin, E.G. Zuhowski, Z. Guo, and K.J. Cullen Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis Clin. Cancer Res. 12 19 2006 5817 5825
146. Z. Yao, A.W. Jones, E. Fassone, M.G. Sweeney, M. Lebiedzinska, and J.M. Suski PGC-1beta mediates adaptive chemoresistance associated with mitochondrial DNA mutations Oncogene 32 20 2013 2592 2600
147. L. Yin, L. Huang, and D. Kufe MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress J. Biol. Chem. 279 44 2004 45721 45727
148. Y. Yoshida, H. Izumi, T. Torigoe, H. Ishiguchi, H. Itoh, and D. Kang P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA Cancer Res. 63 13 2003 3729 3734
149. Y.H. Zeidan, R.W. Jenkins, and Y.A. Hannun Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway J. Cell Biol. 181 2 2008 335 350
150. X. Zhang, M. Fryknas, E. Hernlund, W. Fayad, A. De Milito, and M.H. Olofsson Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments Nat. Commun. 5 2014 3295
151. J. Zhou, Y.H. Wei, M.Y. Liao, Y. Xiong, J.L. Li, and H.B. Cai Identification of cisplatin-resistance associated genes through proteomic analysis of human ovarian cancer cells and a cisplatin-resistant subline Asian Pac. J. Cancer Prev. 13 12 2012 6435 6439
152. H. Zhu, T. Yoshimoto, and T. Yamashima Heat shock protein 70.1 (hsp70.1) affects neuronal cell fate by regulating lysosomal acid sphingomyelinase J. Biol. Chem. 289 40 2014 27432 27443